The REZOLVE-AA trial has reported durable hair regrowth in patients treated with rezpegaldesleukin, according to data covered by Dermatology Times under the headline "REZOLVE-AA Data Show Durable Hair Regrowth With Rezpegaldesleukin."

The word doing the heaviest lifting in that headline is "durable." For alopecia areata, durability has become the central unresolved question of the current treatment era. The approved JAK inhibitors can regrow hair; whether they hold it — and what happens on withdrawal — is what separates a maintenance therapy from a cycle of relapse and retreatment.

What is rezpegaldesleukin?

Rezpegaldesleukin is an investigational selective cytokine agonist designed to preferentially expand regulatory T cells through the interleukin-2 pathway. The mechanism marks a deliberate departure from the JAK inhibition strategy that dominates the current alopecia areata pipeline.

The logic is straightforward: rather than broadly suppressing the inflammatory signaling driving follicular immune privilege collapse, the agent attempts to restore tolerance. Regulatory T cells are positioned upstream of the autoimmune process, and a Treg-selective approach theoretically offers disease modification rather than symptom control.

That is the framework REZOLVE-AA was built to test.

How durable is the response?

The reported headline finding — durable hair regrowth — answers the durability question affirmatively for this dataset, but the publicly available summary does not specify the effect sizes, the response thresholds used, or the length of the durability window measured.

Those specifics matter for clinicians. Key open questions that full publication will need to address include:

• The proportion of patients achieving clinically meaningful regrowth, and on what endpoint
• How long response persisted after treatment, and whether it survived treatment discontinuation
• Dosing schedule, administration route and treatment-emergent adverse events
• Performance in the program's placebo or comparator arms, where applicable

The REZOLVE-AA designation indicates a dedicated registrational-track program in alopecia areata, which positions these durability data as potentially pivotal rather than merely exploratory.

Why durability dominates the alopecia areata conversation

The durability question is not academic. It determines the practical shape of therapy: continuous treatment, intermittent retreatment, or a finite induction course with sustained remission.

For patients, the difference is equally concrete. Alopecia areata carries heavy psychological burden, and relapse after visible regrowth is among the most distressing events in the disease course. A therapy that maintains response without indefinite immunosuppression would shift the risk-benefit calculation materially.

An IL-2 pathway approach also carries a different safety discussion than JAK inhibition, whose class labeling reflects broader pathway effects. Whether rezpegaldesleukin's regulatory T-cell selectivity translates into a cleaner tolerability profile is a question the trial data will be read against.

Where this fits in the competitive field

The alopecia areata market is in its early innings of therapeutic diversification. JAK inhibitors established that pharmacologic reversal of extensive disease is achievable. The next phase of competition will be decided on durability, safety with long-term use, and convenience.

A positive durability signal from a non-JAK mechanistic class widens the field. It gives clinicians a potential future option for patients who relapse on, do not respond to, or cannot take JAK inhibitors — and it validates regulatory T-cell expansion as a viable strategy in autoimmune skin disease more broadly.

What comes next

Full presentation of the REZOLVE-AA dataset — effect sizes, durability windows, and safety detail — will determine how the dermatology community weighs these results against the established JAK inhibitor data. The durability finding itself, as reported by Dermatology Times, gives the rezpegaldesleukin program its clearest signal yet that selective IL-2 pathway agonism may hold a durable place in the alopecia areata treatment paradigm.

Editor's note: This report is based on the headline and framing of the original coverage; readers should consult the primary data presentation and peer-reviewed publication for complete efficacy and safety figures.